Figure 4. Expansion of Tregs after treatment of BDF1 mice with T cell-targeted PLGA NPs encapsulated with IL-2/TGF-β associates with reduced lupus manifestations.
A. Percentages of peripheral CD4+ and CD8+ Tregs at the indicated time points after treatment (x axis). *P<0.05; **P<0.005 in the comparison between unconjugated NPs vs. NPs coated with anti-CD4/CD2 Ab. B. ELISA measurements of anti-dsDNA antibodies from sera collected at the indicated time points. *P<0.05 vs unconjugated NPs. C. Proteinuria at the indicated time points in the mice shown in panel A. *P<0.05 vs unconjugated NPs. Each group included 12 mice.